Acute Myeloid Leukemia (non-APL) · line 1 · 7+3 Induction (cytarabine + daunorubicin/idarubicin) ± midostaurin
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-AML-7-3 |
| ID | IND-AML-1L-7-3 |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-AML |
| Sources | SRC-ELN-AML-2022 SRC-NCCN-AML-2025 SRC-RATIFY-STONE-2017 |
Notes
Aggressive track for AML 1L. Fit-vs-unfit triage is the dominant decision; ELN 2022 risk stratification drives post-CR1 pathway (consolidation HiDAC vs alloHCT). FLT3 status drives addition of midostaurin. STUB — requires clinical co-lead signoff.
Used By
Algorithms
ALGO-AML-1L- ALGO-AML-1L
Indication
IND-AML-1L-7-3-GO-CBF- IND-AML-1L-7-3-GO-CBF